Abstract:Abstract Background Inflammatory bowel diseases (IBD) are chronic, heterogeneous, and inflammatory conditions mainly affecting the gastrointestinal tract. Currently, endoscopy is the gold standard test for assessing mucosal activity and healing in clinical practice; however, it is a costly, time-consuming, invasive, and uncomfortable procedure for patients. There is, therefore, a need for sensitive, specific, fast and non-invasive biomarkers for the diagnosis of IBD. Methods Label-free quantification by nanoscale liquid chromatography coupled to tandem mass spectrometry (nLC MS/MS) was performed to profile the urinary and serum proteomes of 100 patients with newly diagnosed IBD, before starting any treatment [50 patients with Crohn′s disease (CD) and 50 patients with ulcerative colitis (UC)] and 50 healthy controls (HC). Data Mining and Pattern Recognition techniques were used to identify hidden relationships that are not detectable by using the classical and most commonly used lineal classifiers; and thus, identifying potential markers able to discriminate the studied cohorts. Finally, we applied Ingenuity Pathway Analysis (IPA) to analyze the pathways and functions of differentially expressed proteins. Results Serum proteomics results revealed 45 differentially expressed proteins in the comparison between UC and HC groups, 32 proteins significantly expressed in CD versus HC, and 12 proteins in CD compared with UC. In urine samples, 110 proteins were significantly changed in UC versus HC, 50 proteins were differentially expressed between CD and HC, and a total of 31 proteins were significantly changed in CD compared with UC patients. Receiver operating characteristic curve (ROC) analysis found multiple proteins with high area under the curve values, up to 0.94, indicating that these serum and urine proteins are of value as new non-invasive diagnostic classifiers of IBD patients. For each study comparative, the 5 most significant classifiers were selected (Figures 1 and 2). IPA revealed multiple signaling pathways, including prothrombin activation, acute phase response signaling, complement and coagulation system and liver X receptor/retinoid X receptor (LXR/RXR) activation, altered in IBD patients compared to HC (p-value < 0.05) (Figures 3 and 4). Conclusion Our findings indicate that analysis of the urine and serum proteome using nLC MS/MS is a feasible approach for biomarker discovery. We identified several serum and urine proteins that could serve as new non-invasive markers for the diagnosis of IBD patients after further validation. After bioinformatic analyses, we found multiple proteins that may play important roles in the pathogenesis of IBD.

A protease activity-based machine-learning approach as a complementary tool for conventional diagnosis of diarrhea-predominant irritable bowel syndrome

Diagnostic value of serum proteome characters analyzed by proteomic fingerprint technology in patients with inflammatory bowel disease

Dual-Locked Chemiluminescent Probe Enables Precise Imaging and Timely Diagnosis of Colitis Via Chymotrypsin/Vanin-1 Cascade Activation

Application of SWATH Mass Spectrometry and Machine Learning in the Diagnosis of Inflammatory Bowel Disease Based on the Stool Proteome

Characteristics of Fecal Microbiota and Machine Learning Strategy for Fecal Invasive Biomarkers in Pediatric Inflammatory Bowel Disease

TMT proteomics analysis of intestinal tissue from patients of irritable bowel syndrome with diarrhea: Implications for multiple nutrient ingestion abnormality

Fecal proteolytic profiling of pediatric inflammatory bowel disease: A pilot study

Aggregation and Self-Assembly of Hydrophobins from Trichoderma Reesei: Low-Resolution Structural Models

Gut microbial signatures of patients with diarrhea-predominant irritable bowel syndrome and their healthy relatives

Altered gut microbial functional pathways in people with Irritable Bowel Syndrome enable precision health insights

P106 Identification of urine and serum diagnostic biomarkers of inflammatory bowel disease using a proteomic approach

Comprehensive profiling of the human fecal proteome from IBD patients with DIA‐MS enables evaluation of disease‐relevant proteins

P018 Proteomic profile of serum and urine in newly diagnosed patients with Inflammatory Bowel Disease: new approach for biomarker discovery

Noninvasive, microbiome-based diagnosis of inflammatory bowel disease

Mass Spectrometry-Based Metabolomics for Irritable Bowel Syndrome Biomarkers

A psychological symptom based machine learning model for clinical evaluation of irritable bowel syndrome

Leveraging 16S rRNA Microbiome Sequencing Data to Identify Bacterial Signatures for Irritable Bowel Syndrome

IDENTIFICATION OF GUT MICROBIOTA AND METABOLITES SIGNATURE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME

Utilising lipid and, arginine and proline metabolism in blood plasma to differentiate the biochemical expression in functional dyspepsia (FD) and irritable bowel syndrome (IBS)

The use of a gas chromatograph coupled to a metal oxide sensor for rapid assessment of stool samples from irritable bowel syndrome and inflammatory bowel disease patients

Leveraging Human Microbiome Features to Diagnose and Stratify Children with Irritable Bowel Syndrome